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Objective: To assess the efficacy and safety of cinnarizine for the prophylaxis of migraine associated vertigo in the
vestibular migraine and migraine with brainstem aura.
Background: Vestibular migraine and migraine with brainstem aura are two principal clinical syndromes that frequently
are associated with vertigo. Since cinnarizine is a well-tolerated calcium channel blocker which has acceptable effect on
both vertigo and migraine headache, we carried out this study to evaluate the efficacy and safety of this medication in
vestibular migraine and also migraine with brainstem aura associated with vertigo.
Methods: This was a retrospective, single-center, open-label, investigation of the effects of cinnarizine on vestibular
migraine and migraine with associated with vertigo. We assessed the change in monthly frequency of vertigo and also
frequency, duration and intensity of migraine attacks after one, two and three months of cinnarizine administration.
Results: The mean frequency of vertigo and also the mean frequency, duration and intensity of migraine headaches per
month were reduced significantly after three months of cinnarizine therapy (all p < 0.001).
Conclusion: This study suggests that cinnarizine is safe and effective in reducing both headache and vertigo aspects of
“migraine plus vertigo” among the patients who suffer from either vestibular migraine or migraine with brainstem aura
associated with vertigo.
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Migraine and vertigo are two of the most common dis-
orders in the general population that they tend to occur
together (Mehmet 2011). Recent studies suggest that the
comorbidity is about 3.2% and up to 25% of patients
with migraine may experience vertigo (Neuhauser 2009).
Meanwhile, migraine has been considered as one of the
most frequent disorders that causes vertigo according to
various epidemiological studies (Riina et al. 2005; Vuković
et al. 2007). Vestibular migraine (VM) (or migrainous ver-
tigo) and migraine with brainstem aura (BM) (previously
known as basilar-type migraine) are two principal clinical
syndromes that are associated with vertigo (Neuhauser
2009; Brandt 2004). The International Headache Society* Correspondence: toghae@sina.tums.ac.ir
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in any medium, provided the original work is p(IHS) has accepted both VM and BM as migraine variants
and has indicated that only a minority of VM patients
experience vertigo in the time frame of 5–60 minutes
that is defined for an aura symptom. On the other hand,
IHS requires an aura with two or more brainstem aura
symptoms in addition to visual, sensory or dysphasic aura
symptoms to qualify as BM criteria. Thus, these variants
should be considered as two different migraine types
(Society HCCotIH 2013).
Several studies suggest that medications used for mi-
graine prophylaxis may also be effective in comorbidity of
migraine and vertigo (Reploeg and Goebel 2002; Waterston
2004; Dieterich and Brandt 1999). Cinnarizine (CIN) is a
well-tolerated L-type calcium channel blocker which has
early onset effects on migraine prophylaxis (Togha et al.
2006; Mansoureh et al. 2008). While, CIN directly inhibits
vestibular hair cells stimulation (Arab et al. 2004) and also
has antihistaminic actions (Pianese et al. 2002), it seems to
be a good choice in treatment of migraine with vertigo.
However, to the best of our knowledge, no investigationan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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in the treatment of migraine and vertigo comorbidities.
Therefore, we carried out this retrospective study to
evaluate the efficacy and tolerability of CIN in vestibular
migraine and also migraine with brainstem aura associ-
ated with vertigo.
Methods and patients
This was a retrospective, single-center, open-label, in-
vestigation of the effects of cinnarizine (CIN) on mi-
graine associated vertigo in vestibular migraine (VM)
and migraine with brainstem aura (BM) that conducted
in the headache clinic of Neurology Department, Tehran
University of Medical Sciences with both physician- and
self-referred patients. The study protocol was approved by
the ethics committee of Tehran University of Medical
Sciences.
Inclusion and exclusion criteria
Vestibular migraine (VM) and migraine with brainstem
aura (BM) were defined according to the criteria of the
Headache Classification Committee of the International
Headache Society (IHS) 3rd edition (beta version) (Lempert
et al. 2012; Society HCCotIH 2013). Additional inclusion
criteria that specified patients were as follows: men and
women, age between 18 and 60 years, reporting of vertigo
in more than 50% of attacks, a history of migraine for at
least one year, onset of migraine before the age of 50.
Patients were included in the study group if they met all
these criteria and also had at least one return visit after
CIN was prescribed and if the patients stated that they
had consistently taken the medication. At the time of the
prescription neither the patients nor the physician knew
of the investigation.
Study design
Patients complaining vertigo regardless of vertigo attacks
time (during the headaches or between the headache at-
tacks) who met all entry criteria were categorized into
two different groups of VM-group and BM-group. All of
the data were collected from the patients’ headache diaries
in which all vertigo attacks, migraine attacks, duration of
attacks (hours), and intensity of attacks (assessed by a 10-
score Visual Analog Scale (VAS), which “0” indicating no
pain and “10” the worst pain imaginable) were recorded.
Cinnarizine treatment regimen was initiated by a 37.5-mg
tablet (Cinnageron Tablets, G. Streuli & Co. AG, Uznach)
at bedtime for the first three days and then 75-mg tablet at
bedtime for the remaining treatment period. Office follow-
up visits were performed one, two and three months
after the CIN treatment initiation and the change in
monthly frequency of vertigo attacks and migraine attacks
during the study were considered as the main and primaryoutcome, while secondary variables were duration of mi-
graine attacks in hours and intensity of the attacks (VAS).
From the first visit on, patients were asked if they had
experienced any adverse events. Although we recorded
all the adverse events, special attention was paid to oc-
currence of weight gain and extra pyramidal symptoms.
Statistical analysis
Data are expressed as mean ± standard deviation unless
otherwise stated. For intergroup continuous variables com-
parisons One-way ANOVA or Kruskal-Wallis tests were
used. For post hoc Turkey HSD or Bonferroni adjusted
Mann–Whitney test was used. For within group compari-
sons of continuous variables, paired sample student t-test
or Wilcoxon sign test was applied. For binomial variables,
Fisher’s exact tests or Pearson’s chi-square tests were done
for between-group comparisons. Two-sided p value less
than 0.05 considered as statistically significant for all tests.
Data were analyzed using SPSS Statistics version 20. (SPSS
Inc., Chicago, IL, USA).
Results
The study included twenty-four subjects with VM (23
women, 1 man) and sixteen subjects with BM (12 women,
4 men). The ages of subjects ranged from 18 to 54 years
(mean, 30.0 years). Two (5%) of the 40 subjects were lost
to follow up and did not return after the two months on
CIN. None of the remaining patients discontinued the
CIN treatment due to adverse events or any other causes.
Demographic and baseline headache characteristics were
similar except for the mean attacks duration which was
higher in the BM-group (Table 1).
Patients with vertigo (total vertigo population)
Since, vertigo was a common symptom in our all 40 sub-
jects; so we first assessed the efficacy of CIN in migraine
with vertigo regardless of patients’ migraine type. The
overall reduction in the frequency, duration and inten-
sity of the migraine attacks was substantial. The mean
frequency and duration of migraine headaches per month
were reduced from 4.02 ± 1.2 and 26.20 ± 15.3 hours at
baseline to 1.10 ± 0.9, 4.18 ± 3.6 hours at the final visit, re-
spectively (all p < 0.001). The median and range of head-
aches’ intensity (VAS) were also decreased from 8 (7–10)
at baseline to 3 (0–8) at the final visit (p < 0.001). Improve-
ment was noted in most patients as early as at one month
compared with baseline (Table 2).
Vestibular migraine
In the VM-group, the mean frequency of migraine head-
aches per month decreased from 3.92 ± 0.9 before starting
the medication to 0.75 ± 0.7 (p < 0.001) at the last visit. The
mean duration and median intensity of migraine headaches
per month were also reduced from 23.58 ± 15.8 hours and
Table 1 Demographics and baseline characteristics
Variable Vestibular migraine
(n = 24)
Migraine with brainstem aura
(n = 16)
p-value
Age, years (mean ± SD) 31.2 ± 8.0 28.4 ± 11.0 0.084
Duration of migraine (mean ± SD) 7.23 ± 7.2 7.94 ± 4.8 0.291
Baseline monthly frequency of migraine attacks (mean ± SD) 3.92 ± 0.93 4.19 ± 1.5 0.845
Baseline monthly duration of migraine attacks, hours (mean ± SD) 23.6 ± 15.8 30.1 ± 14.1 0.011
Baseline monthly intensity of migraine attacks, VAS (median (range)) 8 (7–10) 9 (7–10) 0.087
SD = standard deviation.
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(min: 0 – max: 5) at the final visit, respectively (p < 0.001).
The reductions in all three efficacy variables were signifi-
cant at every time point after one month. The greatest re-
duction in frequency and duration of attacks was seen
during the second month of treatment, with the frequency
reduced to 0.71 ± 0.8 migraine headaches per month, and
the average duration of migraine headaches dropped to
3.46 ± 4.1 hours per month (p < 0.001) (Table 2).
Migraine with brainstem aura
In the BM-group, the mean frequency of migraine head-
aches per month decreased from 4.19 ± 1.5 before starting
the cinnarizine to 1.62 ± 1.0 (p < 0.001) at the last visit.Table 2 Headache characteristics before and after treatment
Variable Total vertig
population (n
Monthly frequency of migraine attacks (mean ± SD)
At baseline 4.02 ± 1.2
12-week treatment period
1st 4-week 2.35 ± 1.1
2nd 4-week 1.30 ± 1.2
3rd 4-week 1.10 ± 0.9
Monthly duration of migraine attacks, hours (mean ± SD)
At baseline 26.20 ± 15
12-week treatment period
1st 4-week 14.78 ± 6.3
2nd 4-week 5.68 ± 5.1
3rd 4-week 4.18 ± 3.6
Monthly intensity of migraine attacks,
VAS (median, Max.-Min.)
At baseline 8 (7–10)
12-week treatment period
1st 4-week 6 (4–10)*
2nd 4-week 3 (0–9)*
3rd 4-week 3 (0–8)*
VAS Visual Analog Scale.
*p < 0.05 compared with baseline.
1p-value for comparison between vestibular migraine and migraine with brainstemThe duration and median intensity of migraine headaches
per month were also reduced from 30.12 ± 14.1 hours and
9 (min: 7-max: 10) at baseline to 6.56 ± 3.2 hours and 4
(min: 2-max: 8) at the final visit, respectively (p < 0.001).
The reductions in all three efficacy variables were signifi-
cant at every time point after one month (Table 2).
Comparison between the two migraine types
Although CIN has significantly improved efficacy vari-
ables in both VM- and BM-groups, reduction in these
variables was significantly greater in VM-group. Except
for baseline monthly duration of migraine attacks, all
other demographic and baseline headache characteristics







aura (n = 16)
p-value1
3.92 ± 0.9 4.19 ± 1.5 0.845
* 1.92 ± 0.6* 3.00 ± 1.3* 0.001
* 0.71 ± 0.8* 2.19 ± 1.0* <0.001
* 0.75 ± 0.7* 1.62 ± 1.0* 0.004
.3 23.58 ± 15.8 30.12 ± 14.1 0.011
* 13.88 ± 7.0* 16.12 ± 4.9* 0.066
* 3.46 ± 4.1* 9.00 ± 4.6* 0.001
* 2.58 ± 3.0* 6.56 ± 3.2* <0.001
8 (7–10) 9 (7–10) 0.087
5 (4–9)* 7 (5–10)* 0.005
1 (0–7)* 5 (2–9)* <0.001
1 (0–5)* 4 (2–8)* <0.001
aura.
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and intensity of migraine attacks per month compared
with the patients who fulfilled the criteria for migraine with
brainstem aura (p < 0.01). Although the mean duration of
migraine headaches per month was significantly shorter in
the VM-group at the baseline, it becomes similar in both
groups after one month (p = 0.066) and again after the sec-
ond and third months, greater reduction was seen in the
mean duration of monthly migraine headaches among the
patients with VM.
Vertigo
In the BM-group and VM-group, the mean frequency of
vertigo per month decreased from 3.50 ± 0.89 and 3.79 ±
1.14 before starting the cinnarizine to 1.62 ± 1.0 and 0.42 ±
0.65 at the last visit, respectively (p < 0.001). Meanwhile,
the reductions of vertigo frequency were significant at
every time point after one month (Table 3). Although sig-
nificant reductions in monthly frequency of vertigo were
seen in both subgroups, the reductions were not signifi-
cantly different when compared between the subgroups.
Overall 9 subjects (22.5%) reported adverse events during
the study period. 5 subjects (12.5%) experienced weight
gain, 3 subjects (7.5%) reported blurred vision, and one pa-
tient (2.5%) reported somnolence. Neither of our subjects
experienced parkinsonism during the study.
Discussion
Our experience suggests that CIN is safe and effective in
reducing the frequency of vertigo attacks as well as fre-
quency, duration and intensity of migraine headaches
among the patients who suffer from either vestibular mi-
graine or migraine with brainstem aura associated with
vertigo. Although, CIN worked effectively with both types
of migraine, reducing the headache characteristics (fre-
quency, duration and intensity) by a statistically significant
level in the first month of treatment, the medication was
more effective in vestibular migraine subtype. On the other
hand, the frequency of vertigo attacks was not reduced dif-
ferently between subtypes that this finding may reveal vari-
ous aspects of CIN in migraine treatment and can beTable 3 Vertigo frequency before and after treatment with ci
Variable, mean ± SD Total vertigo
population (n = 40) Vestibular
Monthly frequency of vertigo attacks
At baseline 3.68 ± 1.05 3.7
12-week treatment period
1st 4-week 1.30 ± 1.07* 1.5
2nd 4-week 0.60 ± 0.67* 0.7
3rd 4-week 0.35 ± 0.65* 0.4
*p < 0.05 compared with baseline.
1p-value for comparison between vestibular migraine and migraine with brainstemconsidered that CIN has independent effects on vertigo and
headache characteristics of “migraine plus vertigo”. How-
ever, these findings should be confirmed by other studies.
Cinnarizine is a selective calcium channel blocker that
has been used to prevent and treat vertigo. Several studies
reported extrapyramidal reactions and depression that were
induced by CIN. However, these adverse events are usually
described in elderly patients with prolonged CIN therapy
(Negrotti and Calzetti 1997; Martí‐Massó and Poza 1998;
Micheli et al. 1987). Overall 22.5% of our subjects reported
adverse events with CIN, which all were mild to moderate,
and no serious side effects such as extrapyramidal reactions
or depression were reported during the medication ad-
ministration. Meanwhile, some previous studies have also
shown that this medication can be well tolerated in pa-
tients suffering from migraine (Mansoureh et al. 2008;
Togha et al. 2006).
In two different recent studies, authors concluded that
cinnarizine, either alone or in combination with dimenhy-
drinate is an effective and well-tolerated option for treat-
ment of vertigo with various origins (Scholtz et al. 2012;
Hahn et al. 2011).
Some studies reveal that prophylactic treatments for
migraine such as ergots and beta-blockers are efficient
in preventing migraine related vertigo (Tusa 2000). But,
these drugs have limitations to use in asthmatic and car-
diovascular diseases. It is difficult to interpret most of these
studies, because they assessed different disease entities, and
thus, cannot be compared directly.
However, in a retrospective study, Baier et al. compared
the treatment response of VM in a group of patients who
received prophylactic medications such as beta-blockers,
valproic acid, topiramate, lamotrigine, amitriptyline and
flunarizine, with another group who did not receive any
prophylactic medications, and reported that patients with
medical prophylaxis experienced a reduction in frequency
(80%), intensity (68%) and duration (65%) of the episodic
vertigo attacks (Baier et al. 2009). In another study which
investigated the efficacy of lamotrigin in migraine related
vertigo, the authors reported that the mean vertigo fre-
quency per month was significantly decreased from 8.1 tonnarizine
Subgroups
migraine (n = 24) Migraine with brainstem aura (n = 16) p-value1
9 ± 1.14 3.50 ± 0.89 0.372
4 ± 1.10* 0.94 ± 0.93* 0.079
9 ± 0.72* 0.31 ± 0.48* 0.016
2 ± 0.65* 0.25 ± 0.58* 0.402
aura.
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month was not significant (Bisdorff 2004). In another retro-
spective study (Bikhazi et al. 1997) authors reported that
only little improvement was seen in either headache or diz-
ziness in the 22 patients taking calcium-channel blockers,
beta-blockers, antidepressants, valproic acid, methylsergide
and cyproheptadine. In contrast, Reploeg et al. reported a
dramatic amelioration (72% of the 81 patients) of vertigo
attacks with tricyclic antidepressants or beta-blockers in
81 patients with nonspecific migraine-associated vertigo
(Reploeg and Goebel 2002).
Conclusions
However, although our study was small and studies with
larger sample sizes and longer follow-up durations are
needed to assess the efficacy and safety of CIN in mi-
graine related vertigo, the results of this study are robust
and show that CIN may be considered as an excellent
choice for treatment of migraine and vertigo comorbidi-
ties and particularly vestibular migraine.
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